Eli Lilly has yet to publish the full results, which means the data has not been peer reviewed or independently verified, so experts have only been able to comment on the press release.
Alzheimer drugs: How donanemab compares to lecanemab...
Alzheimer drugs: How donanemab compares to lecanemab...